{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:07:21Z","timestamp":1718723241285},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,10,15]]},"DOI":"10.2169\/internalmedicine.8968-21","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:10:07Z","timestamp":1647641407000},"page":"3107-3110","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Abscopal Effect of Low-dose Radiotherapy (2 Gy \u00d72) against Palatine Tonsil Follicular Lymphoma"],"prefix":"10.2169","volume":"61","author":[{"given":"Kazuto","family":"Togitani","sequence":"first","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Asagiri","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kochi Medical School Hospital, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95: 316-327, 2020.","DOI":"10.1002\/ajh.25696"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King&apos;s College Hospital experience. Br J Haematol 190: e279-e282, 2020.","DOI":"10.1111\/bjh.16935"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cerrato M, Orlandi E, Vella A, et al. Efficacy of low-dose radiotherapy (2 Gy \u00d72) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas. Br J Radiol 94: 20210012, 2021.","DOI":"10.1259\/bjr.20210012"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Saleh K, Michot JM, Schernberg A, et al. Repeated courses of low-dose 2\u00d72 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. Cancer Med 9: 3725-3732, 2020.","DOI":"10.1002\/cam4.2796"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer 40: 25-37, 2016.","DOI":"10.1016\/j.currproblcancer.2015.10.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 356: 82-90, 2015.","DOI":"10.1016\/j.canlet.2013.09.018"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. MacManus MP, Hofman MS, Hicks RJ, et al. Abscopal regressions of lymphoma after involved-site radiation therapy confirmed by positron emission tomography. Int J Radiation Oncol Biol Phys 108: 204-211, 2020.","DOI":"10.1016\/j.ijrobp.2020.02.636"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Miyoshi H, Sato K, Yoshida M, et al. CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t (14;18) and poor prognosis. Pathol Int 64: 95-103, 2014.","DOI":"10.1111\/pin.12145"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li Y, Hu S, Zuo Z, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol 28: 787-798, 2015.","DOI":"10.1038\/modpathol.2015.42"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sekiguchi Y, Imai H, Wakabayashi M, et al. CD5-positive follicular lymphoma: a case report and literature review. Intern Med 50: 899-904, 2011.","DOI":"10.2169\/internalmedicine.50.4339"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Patel N, Durkin L, Bodo J, Hsi ED. Immunohistochemical expression of lymphoid enhancer binding factor 1 in CD5-positive marginal zone, lymphoplasmacytic, and follicular lymphomas. Am J Clin Pathol 153: 646-655, 2020.","DOI":"10.1093\/ajcp\/aqz207"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Menter T, Trivedi P, Ahmad R, et al. Diagnostic utility of lymphoid enhancer binding factor 1 immunohistochemistry in small B-cell lymphomas. Am J Clin Pathol 147: 292-300, 2017.","DOI":"10.1093\/ajcp\/aqw208"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 92: 267-268, 2007.","DOI":"10.3324\/haematol.10682"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Russo AL, Chen YH, Martin NE, et al. Low-dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys 86: 121-127, 2013.","DOI":"10.1016\/j.ijrobp.2012.12.024"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol 22: 332-340, 2021.","DOI":"10.1016\/S1470-2045(20)30686-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matt S, Hofmann TG. The DNA damage-induced cell death response: a roadmap to kill cancer cells. Cell Mol Life Sci 73: 2829-2850, 2016.","DOI":"10.1007\/s00018-016-2130-4"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106: 3150-3159, 2005.","DOI":"10.1182\/blood-2005-02-0553"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Knoops L, Haas RLM, de Kemp S, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 110: 1116-1122, 2007.","DOI":"10.1182\/blood-2007-01-067579"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Walle T, Monge RM, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol 10: 1-27, 2018.","DOI":"10.1177\/1758834017742575"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Rodriguez-Ruiz ME, Rodriguez I, Garasa S, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 76: 5994-6005, 2016.","DOI":"10.1158\/0008-5472.CAN-16-0549"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rees GJ. Abscopal regression in lymphoma: a mechanism in common with total body irradiation? Clin Radiol 32: 475-480, 1981.","DOI":"10.1016\/S0009-9260(81)80310-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 15: 424-435, 2014.","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ollila TA, Lu S, Masel R, et al. Antibody Response to COVID-19 vaccination in adults with hematologic malignant disease. JAMA Oncol 7: 1714-1716, 2021.","DOI":"10.1001\/jamaoncol.2021.4381"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/20\/61_8968-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T03:26:35Z","timestamp":1665804395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/20\/61_8968-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":23,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8968-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"article-number":"8968-21"}}